Brooklyn ImmunoTherapeutics Return on Equity

Brooklyn ImmunoTherapeutics (BTX) currently reports a ROE of -4.91%. That is below the Telecommunications sector average of 1.18%. Use the charts on this page to explore Brooklyn ImmunoTherapeutics's ROE history and peer comparisons.

Brooklyn ImmunoTherapeutics's ROE of -4.91% is lower than the Telecommunications sector average of 1.18%. That is roughly 514.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Brooklyn ImmunoTherapeutics's current -4.91% should be judged against Telecommunications norms (sector average: 1.18%) and against BTX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -4.91%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Telecommunications average is 1.18%. From there, open related valuation or income-statement pages for Brooklyn ImmunoTherapeutics, and consider following BTX for alerts when major investors trade the stock.

Brooklyn ImmunoTherapeutics is classified in the Telecommunications sector. On ROE, it currently shows -4.91% versus a sector average near 1.18%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Telecommunications are usually more informative than comparing BTX with unrelated industries.